| Title |
The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses
|
|---|---|
| Published in |
Cancer Management and Research, August 2012
|
| DOI | 10.2147/cmar.s33979 |
| Pubmed ID | |
| Authors |
Brendon J Coventry, Martin L Ashdown |
| Abstract |
This year marks the twentieth anniversary of the approval by the US Food and Drug Administration of interleukin-2 (IL2) for use in cancer therapy, initially for renal cell carcinoma and later for melanoma. IL2 therapy for cancer has stood the test of time, with continued widespread use in Europe, parts of Asia, and the US. Clinical complete responses are variably reported at 5%-20% for advanced malignant melanoma and renal cell carcinoma, with strong durable responses and sustained long-term 5-10-year survival being typical if complete responses are generated. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 80% |
| Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| Brazil | 1 | 2% |
| Unknown | 59 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 23% |
| Student > Ph. D. Student | 9 | 15% |
| Student > Bachelor | 7 | 11% |
| Other | 7 | 11% |
| Student > Master | 4 | 7% |
| Other | 9 | 15% |
| Unknown | 11 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 23% |
| Agricultural and Biological Sciences | 12 | 20% |
| Immunology and Microbiology | 7 | 11% |
| Biochemistry, Genetics and Molecular Biology | 6 | 10% |
| Chemistry | 2 | 3% |
| Other | 10 | 16% |
| Unknown | 10 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 December 2020.
All research outputs
#3,992,746
of 22,675,759 outputs
Outputs from Cancer Management and Research
#147
of 1,988 outputs
Outputs of similar age
#27,894
of 164,714 outputs
Outputs of similar age from Cancer Management and Research
#5
of 15 outputs
Altmetric has tracked 22,675,759 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,988 research outputs from this source. They receive a mean Attention Score of 2.8. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 164,714 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.